On Sept. 2, 2020, Ceres Nanosciences announced it had been awarded a contract from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. The contract, for $6.5 million, supported an expansion to increase the manufacturing capacity of Ceresﾒ Nanotrapﾮ Virus Particles for COVID-19 tests.?

Ceresﾒ Nanotrap Virus Particles improve diagnostic testing for SARS-CoV-2 by eliminating the need for RNA extraction kits, reducing sample processing time, and improving the sensitivity of the downstream assays in point-of-care systems and in high-throughput laboratory developed tests.